Randomized phase 2 study of weekly carfilzomib 70 mg/m2 and dexamethasone plus/minus cyclophosphamide in relapsed and/or refractory multiple (MM) patients (GEM-KyCyDex)
Borja Puertas,Veronica Gonzalez,Anna Sureda, Ma Jose Moreno,Albert Oriol,Ma Esther Gonzalez,Laura Rosinol,Jordi Lopez,Fernando Escalante,Joaquin Martinez Lopez,Estrella Carrillo,Esther Clavero,Ana Pilar Gonzalez Rodriguez,Victoria Dourdil,Felipe de Arriba de la Fuente,Marta Sonia Gonzalez,Jaime Perez de Oteyza,Miguel Teodoro Hernandez,Aranzazu Garcia Mateo,Joan Blade,Juan Jose Lahuerta Palacios,Jesus San-Miguel,Enrique Ocio,Maria-Victoria Mateos BLOOD（2022）
关键词
cyclophosphamide,weekly carfilzomib,gemkycydex,dexamethasone
AI 理解论文
溯源树
样例
